. >> two months later, investigators found cliff merck's gun. it was in the possession of a man, whom we'll call dan jones, at the time he was arrested on a drug charge. it was easily identifiable since cliff's initials had been carved into the handle. >> that was cliff. he had his name on practically everything that he owned. he'd take some kind of an etcher and etch his initials on it, you know, just for identification. >> jones denied any involvement in the murder and said he bought the gun from an acquaintance, robert cowan, a man well known to law enforcement. >> he had no occupation and he supported himself by stealing, robbing houses, stealing from people outside of restaurants and that type of thing. he had a long record of robberies and use of narcotics. >> robert cowan also had a partner in crime, his brother gerald. >> the brothers were involved in criminal activity, a lot of small-time stuff, public drunk, a lot of narcotics usage, some assaults. >> forensic scientists tested cliff's gun to see if it was the one used in his murder. t

merck is shopping. time yi time, inc. goes off on its own. embarking on new chapters. >>> the white house makes it easier for some students to pay down their debt load and calls for more changes. >>> and kickoff, will one of the world's biggest sporting events help lift south america's biggest economies? we have that all on "nightly business report" for monday, june 9th. >>> good evening, everyone. volatility spiked just a bit in the major averages saw just modest gains, equities did rise for a fourth session in a row and that was enough for the dow, the s&p 500 and the dow transports to close at fresh all-time highs once again. investors got a lift of another round of major mergers and the spin enough of a batch of some household magazine titles from one of the nation's oldest and biggest media companies. here's how stocks ended the day. the dow up sl points. nasdaq added 14. and the s&p ended one point higher. one of the biggest deals announced today was the drug giant merck. agreeing to buy specialty drugmaker identix. shares of dow compon

merck to buy farm suit kals. 180 shares and up.o takeover allergan that is what he was saying earlier. this morning starting off with tyson foods submitting a binding offer to acquire hillshire for $63 a share in cash. valuing the company the maker of jimmy dean sausage for $7.7 billion. the offer contingent on the company to buy pinnacle foods. i'm expecting that will take place. in the meantime pilgrim's pride stayed at $55. what happened here? >> they go to seal bids and you end up paying more than they should have. what has surprised people not the least of whom are at least $1 billion more than they are able to pay. $300 million. they put a deck out and have been asked a lot of questions on the call. let's assume it is $300 million, to $200 million you are paying for the premium you paid above the huge premium that pilgrim's pride was willing to pay. this is not a great company. it was a cast off company. so they split it up. maybe attracting buyebuyers. it would be amazing to get there within five years. we come in today for

are there more things that you might do and what will merck be?ithin five years? will it be cancer? will it be, i don't know, neurological diseases? where are you headed? >> oh, so, to your last point, we're incredibly excited by advances in human genetics, advances in immu -- immunenolog. >> that is one of the major spaces in society. we want to focus on those areas where medical need and 69 tick opportunity overlap. the seam of the consumer business was based on our notion, we said all along, that it didn't have global scale. we are a pharmaceutical company. we are exited to break through research. we want to do it in a productive way. >> and harkening back to andrew's piece, i mean, it does help when a truck company makes a lot of money, doesn't it? it doesn't hurt, our animal health seems to be less risky research and it can be generate a lot of cash. i mean, it's hard to separate theal truistic part of developing drugs with you need enough money to do it, too. >> reporter: i agree with that. again, it goes back to my point. >> that our goal i

but the langharts did not settle, insisting merck be held accountable for what the family said was merck'silure to properly warn users of the risk. according to the study that risk is fewer than 11 cases for 10,000 women who used nuvaring for a year but double the incidence of life-threatening blood clots from older pills. be sure to tune in for my full series of investigative reports on this starting tuesday night 8:00 p.m. eastern time. >>> e-cigarettes and saturday morning cartoons. an odd and troubling pairing that you'll be hearing more about. elizabeth cohen told me why. >> so here's the issue. the people who make e-cigarettes say, hey, these are for adults, but it seems like they're being advertised, according to various experts, on things that kids watch. so channels like comedy central or abc family and mtv. and so there's this real concern that even though they say that they're not advertising to children, that children are certainly seeing these ads. so we're expecting to hear more about that in this coming week. >>> everywhere i go i see people using these e-cigarettes. i read

with that continuation i think that now you saw merck saying, you know what?od one for sale. it was oversold. we're going to pay three times what it was trading for on friday to make sure we buy it. that's why, again, they didn't say that across the board, they didn't go out and buy an etf, they went out and bought one company. liz: and quietly, oil jumps higher jeff. just as everybody's focusing on equities, there has been no correction when it comes to the energy markets. we're looking at oil now above $104 a barrel. what's the next weigh station? where do we go from here? >> well, again, if you look at it from a technical standpoint, we're right at the top of the 90-day moving average or so. the high 104s. the market doesn't break out crude oil until we have a settlement of about 105.25. what was the leader, and i always said this in the past, continues to be the leader is the gasoline. gas was strong all day today, continued even on its last dip. it came back strong right at the close. again, i think what that's showing here is a little bit of anticipation

. >> merck acquiring eidentic sfl. >> merck is flat, so what is actually happening is -- >> gilyard getting hammered. >> a huge marketplace. but some concern that their portfolio is probably a little bit of a threat. i think merck is 7% away from its '08 highs. i think you buy this name. >> almost four years after united/continental mega merger, "wall street journal" calls it one sick bird. >> and i like the stock. it has not been able to manage anything close to what delta did, seamless transition as they merged with the two big entities. i think that might accelerate hopefully toward the second part of the year. stocks had a decent run recently up toward 48. a little bit of a pull back today. but they do have that pricing power and there are just a limited number. this is one of the big boys. you look at the forward pe of 8. a lot of reasons to still love this company. >> achn, up like 40% today. >> and i'll say about it, this is what they should be targeting in my opinion, big phrma, not the 100 billion plus pfizer going if astrazeneca. bioteches under $5 billion gives a great opportunit

. >>> merck is spending near already 4 billion to get its hands on a hepatitis-c drug. >>> plus what one man says is clearly the single worst airline in the america, and the video kind of gave it away. oh my god! look. you need to see this. show 'em the curve. ♪ do you know what this means? the greater the curvature, the bigger the difference. [sci-fi tractor beam sound] ...sucked me right in... it's beautiful. gotta admit one thing... ...can't beat the view. ♪ introducing the world's first curved ultra high definition television from samsung. >>> merck is buying idenix. you can see the shares, up 231%, not a misprint, guys. joining us more with the details and meg tirrell and herb greenberg. good to see you all. meg, big deal here, big deal. >> absolutely, for a really big market today put a price that of -- it's constituented there's $so million worldwide that have hepatitis c. now gilead's stock is actually down today. analysts i'm speaking with today say it's due to intellectual property underlying the drug. merck and iidenix clade they own a part of it, analysts now saying combi

merck, j&j, and avi. >> can't be wrong.hat i'm saying these are smart companies with great research directors or tremendous understanding of where the protein move is going. i had maybe public enemy number one for chipotle. they make bovine growth and they make antibiotics. so when you hear that, you know, we don't want livestock with antibiotics, well, they do that. what are they about? >> right. >> protecting the protein food chain and they said this is the most important thing in the world right now in terms of food. so maybe hillshire, maybe tyson are saying, the stock market doesn't know. this quote from donnie smith yesterday, good brands like hillshire and ballpark and jimmy dean don't come around very often. they hadn't come around. they weren't for sale. it was hostile. >> getting back to the market here because the point i was trying to make, of course, is you say well maybe there shouldn't be complacency. >> they should be -- on the part of the bulls. >> and yet we've been waiting for m&a a long time. i don't wan

merck is buying idenix for $3.9 billion. $24.50 in cash.hepatitis c products. >> up 235%. >> that's remarkable. as bill was saying, this potentially making the point for him about the acquisitions of good ideas. tyson foods outbidding pilgrim's pride in the battle for hillshire. $63 a share in cash. roughly 70% premium to hillshire's price before all that bidding began. and an lag devices is buying hittite. >> i looked it up. it's in genesis. one of the 12 tribes. >> did you take latin? >> i did not. it's 29% premium over friday's close. part of a wave of consolidation. >> mesopotamia. the pershing square capital management ceo. we cut you off in the middle of a thought. do you want to finish that first? >> what has happened since the beginning of the year, the fdc launched a formal investigation. why is that significant? they had 15 months to watch the investigation. for them to launch a formal investigation, again, with a short seller, with all the profile and everything else, means to me it requires a vote of the commissioners. you need

. >> some names ripping 230% on the big merck deal. we'll talk about that coming up and big news-maker interview coming up. tyson ceo donny smith, that's right, he's breaking the bank and winning the bidding war for hillshire brands, paying a whopping $7.8 billion for the maker of jimmy dean sausages, among others. why was he willing to go that high? we'll ask him about that and more in an exclusive interview. >> that's a lot of pork. also on "closing bell" exclusively electronic arts ceo andrew wilson live ahead of the much anticipated e3 conference, making news at this hour as wilson tries to turn ea around. >> and buffeted by talks and federal reserve officials, the damage up as much as 45 points before turning briefly negative a few moments ago. now it's up about 12 points. take a look at the nasdaq which is up about 8. that's the one, again, where we're seeing some support from some of the smaller momo quote, unquote names and the s&p 500 adding shy of a point. 1949 after a week where we hit repeated historic highs. >> joining our

turns out not only merck went identix, so did johnson&johnson and great companies. considering the drug is only in phase two testing and what they're having with help c drugs, i would have never recommended the stock. i thought it was insane and now have to be more aggressive than i was with the small biotechs. i have to redouble my efforts and find companies that could be takeover candidates starting with, yes, seattle. both could have been worth a heck of a lot more than i thought based on what i have seen. and an ms drug is soaring. after identix, who might tell you sell receptives. analog devices buys hittite. worth $2 million a deal that instantly sent up both stocks. hittite. i remember jocking about this company. let's smoke the hittites. the shorts were smoked, a totally under the radar company, soared $77 and change and the 5% gain in the inquirer stock in analog. how about cypress? is the market way too negative about that one now? call me a buyer. finally, family dollar, the worst run of the dollar store. carl icahn takes a big stake, and next you know, d

merck is buying a drug maker. next. we have got the man who wants changes at the top for netflix. the new york city comptroller is explaining why he's fighting the netflix chairman and ceo roles all next. can you start tomorrow? tomorrow we're booked solid. we close on the house tomorrow. tomorrow we go live... it's a day full of promise. and often, that day arrives by train. big day today? even bigger one tomorrow. csx. how tomorrow moves. but what if you could see more of what you wanted to know? with fidelity's new active trader pro investing platform, the information that's important to you is all in one place, so finding more insight is easier. it's your idea powered by active trader pro. another way fidelity gives you a more powerful investing experience. call our specialists today to get up and running. >>> a news alert now on godaddy. >> that's right. godaddy wants to go public filing it's s-1. it had $1.4 billion in total bookings. up from last year. as far as revenues, it had $1.1 billion in revenues. they are not profitable. but believe their bookings are an indication

merck is buying identix. they are a huge winner today. apple's share price.t to you this morning. why is that, nicole? >> at $100. equivalent to $700. today, you have a multi- year high occurring on this. you see it up 1%. 9309 at this moment. there are some findings that they do not necessarily mean greatness. it does make it a little bit more eligible for the dow jones industrial average. we will be waiting on things like the iphone six. more affordable for the people that want to get in there. stuart: thank you very much. men are lagging. 700,000 fewer jobs now than they did in december of 2007 when the recession began. what is this war on women? >> it is a war on jobs. i have been talking about this all weekend. i say that we cannot go back to 2008. we have grown as an economy. the participation rate is at its lowest since 1978 which was under mister carter. we have a situation with the lowest level of people that can't work since 1978. i think that this is indicative. it is lower-level jobs. stuart: you have to give me your answer to the question that ev

merck merck is here to look at then and now. hard to believe it's been 25 years. >> absolutely. at the time so many experts said the public face of the chinese government will be very defiant, but behind closed doors they'll start to make changes. we haven't seen a lot of democratic changes, but we have seen economic changes. there was no stock market in china. it opened in 1990 when it opened in shanghai and shenzhen. and we quote it now as the most normal thing in the world. 1992, they officially endorsed a socialist market economy. forget the socialist part, adding the word market economy for a communist country's economy was earth shaking. 1997, they finally decide most prices will be set by the market. it wasn't that long ago, 1997. 2001, they announced that private entrepreneurs can be members of the communist party, which sets up cognitive dissonance in my head, if you're a communist you don't believe in private property or priority -- but -- it wasn't until ten years ago, 2004, when they finally put in the constitution of protection of private property. that's amazing. >

merck is buys, my friend that covers this says that companies -- that's not a typo, 232% gain. it's dragging dozens of biotechs up with it, some of it leek celldex therapy, we're back again to the biotechs being on in a very big way. low rates means home builders are back. we've had this enormous three-day rally, many of them up 6, 7, 9%. speaking of low yields. this morning e-mails all over, spanish bond yields now below u.s. bondees. as a sign that everybody is saying etf leaders, it looks like january again, socl, that's all the twitters, facebooks, all on the up side. transports doing well. the xsd, the semiconductor index also up. these were the leadership stocks back in january. it's not really emblematic of what is going on. we've seen rallies in groups, then got hurt, now come back. >> but the market likes big round numbers. that's what they're focusing on today. i'll see you later at post 9. ty, up to you. >> sue, thank you very much. there are still a lot of questions about individual investors and morgan brennan has been covering that story for us today. there's stil

the merck deal changed a lot of people's minds, including mine. yes?> boo-yah, jim. >> boo-yah. >> this is my family. >> how are you? thank you for coming. >> i am asking for ensco. you were on -- >> for the charitable trust. why? it yields more than north of five. it's got the newest and best fleet. a lot of people worried about day rates. i'm not concerned. mexico opening up soon. i think ensco is terrific. >> boo-yah, jim. >> boo-yah. >> this is my daughter darren. i'm asking about uvv universal corporation. a tobacco company. >> we like -- that's the one we like. we do believe it will not be independent. that's my play in that group. yes? >> i got let's go rangers, boo-yah, jim. >> well, it's a hopeful boo-yah. >> this is my mom terry. and i've got a question about panera. what's going on? >> when we had ron shake on, i felt he was some degree telling you, listen, we're not ready yet. i think when they have to have two more quarters where i feel like they addressed a lot of the issues he brought up. and then, then not yet. yes. >> i'd like to give

. >> quick, you like gilead and merck. not because you think they're massive winners but good risk reward? >> a big pick for years. this year the stock has been okay, not that exciting. still at the top of my list, though. why? a different call now. gilead, believe it or not, even though the stock quadrupled is a value stock. let me repeat that. it's a value stock. if this stock does nothing in one year trading eight times forward earnings. an eight pe. even if you're bearish on gill yed, hasrd to make the case the stock goes down. risk or reward over the next year or two, heavily skewed up. merck also a pick over the last year and a half, farmside. worked well. no longer cheap. my original thesis, cheap. a value stock. no longer super cheat but in the bottom of the sixth, top of of the seventh inning in terms of investment there. more to come and that stock to break through 60 over the next few months. >> great stuff. thanks for joining us. >>> and scoring a second half victory in your playbook. >> it's real simple. you g

merck paying nearly $4 million that makes the hepatitis c medication and priceline.com will pay $2.6 million to buy the online reservation business opentable.com. >>> president obama took action to help millions of college grads pay down student loan debt signing an executive order expanding a program that set the cap at 10% of a borrower's salary towards pay iing off tho stafford loans. >>> lots of auto industry news this week. ford had to lower the miles per gallon claims it posted are for six of its vehicles. general motors issued its 38th recall of the year. 38th. for another type of defective admission system. toyota recalled 2 million vehicles for a second time over an air bag ib you. and a surprise move by tesla which is opening up its technology patent to any automaker that wants to make long-range electric cars saying the move will had increase development of more and better electric vehicles, lead to more sales akrs the sector, and actually strengthen tesla's share of the market. >>> get all your business news on cnbc. >>> you may have noticed that during you're newscast we

merck, bristol-myers, astra zeneca are giving us a glimpse on how to change cancer treatment. >> for the first time, we have the sense that there is a general mechanism we could employ that could profoundly improve the lives of cancer patience of a whole variety of tumors. it's enormously exciting. >> reporter: if advances for bladder cancer, mile loma, in a market some say could approach $35 billion a year. it was the first big showcase of astra zeneca's pipe lean and they alsoed that data on a combination of drugs and ovarian cancer, which analysts said it could lead to treatments that don't require more toxic lung therapy. a drug looks to be competing with a lower one. the truck shows similar efficacy, stocks took a hit on concerns. other advances came from leukemia. so where do we stand in the fight against cancer? the food and drug administration's director of the office of hematology and oncology has attended 34 straight asco conferences and gave us a test for how tar we have come. >> we have better drugs, a better understanding of the disease. with removing away from cyto toxi

star perform performer, shares are up 19% during that time frame, then there's pharmaceutical giant merck. the single best performing stock in the dow industrials over that timespan has been construction and money for caterpillar. it's up a whopping 34%. now, the question for many investors is, where will the next round of leadership in the stock market come from. >> some of the areas that look attractive for us are the technology space. a lot of next generation technology companies that are focused on cloud and next generation architecture were sold off very hard in march and april. i think also in the discretionary space, some of the mid cap retailers continue to look attractive to us. >> of course, there will be more to consider as well. >> i think you need to keep your eye on interest rates, if they're moving too far too fast, that would probably be the beginning of a more substantial correction of the stock market. >> regardless of the risks, it's important for each individual investor to gauge their own appetite for how much they want to take. >> the thing investors should be most c

merck paid $4.85 billion for its deadly drug vioxx.he dangerous diet pill phen/fen costs 3ds.75 billion. bp paid $7.8 billion for poisoning the gulf of mexico but nothing compares to the tobacco industry coughing up $260 billion. the costs for gm will likely run into the billions, no question. cost of the recalls, payouts to victims' family, lost value of used cars, fines from the government. to say nothing of the reputation hit as angry families grieve. >> it's not about the money. we want -- >> not about the money. >> reporter: still, gm has deep pockets. in the years since taxpayers pailed it out in 2009, at a cost of $10.6 billion, gm sales are up. in fact, surging since the ignition defect recall was announced in february. seems consumers think gm really messed up, but they don't associate gm with the car brand they want to buy. >> the vast majority of people don't know that buick and cadillac and gmc are gm products. very interesting bifurcation between the image general motors has and the image that its brands have. >> reporter:

and then the pharmaceutical giant, merck, based in new jersey, has agreed pay nearly $4 billion for pharmaceuticals, company that develops drug for hepatitis. so, we'll see if the markets can keep up the rallies today, nicole, erika? >> jill, of course, we've talk about this before. but now, even more companies raising the price of a cup of coffee, right? >> horrible news. >> i know. >> yes, not what we earlier risers want to hear. cost of the morning cup of coffee just keeps ongoing up. dunkin's ceo now says that coffee prices will likely go up in stores, but only by a little, he says, because franchise owners might want to raise the price on items like donuts, breakfast sandwiches, because just coffee, he says, really such a important market. last week the price for folger's and maxwell house, that jumped about 10 percent, this is all being blamed on the drought, and higher coffee bean prices. there is one positive side, starbucks, says it, won't be raising prices just jet because the company did buy its coffee beans way in advance. >> so expensive coffee will just stay expensive, all right. >> e

merck is putting super phenomena through a six week human trials genetically enhanced rich claimed they could improve the diet of people in east africa but scientists michael hansen thinks this is nothing more than a publicity stunt to improve the reputation of g.m. giants things like golden rice or golden bananas are attempts to say oh we can use this technology for a useful purpose that will help the poor so i see it more as propaganda purposes and i think the reason that they are trying so desperately with the genetic engineering is it does have a bad name eighty five percent of the global acreage in engineered crops are all herbicide tolerant they're designed to be sprayed with herbicides they're doing they're designed to have you spray more pesticides on them part of the problem is in the in the united states for example we don't require safety assessments or feeding studies before these products are allowed on the market before these are even fed to people they should go through a safety assessment. to be fed you know not only to animals or they're given to humans because in other

. >> merck was on this morning.ou think merck is going to make the number by just discovering fabulous new drugs? you make the number by saying you know what, we got to streamline. lily has been streamlined. you have some industries that are -- you have big guys laying off or streamline. these companies they just don't have to hire when someone leaves. then biotech is not hiring. all the ipos used to hire people, they died. >> yeah. and the numbers are still small. i mean when we bring on one of these emerging companies or recently public companies how many people are you going to hire? 50, 100. good paying jobs but they're not the thousands that conceivably will be lost as a result of consolidation, which is potentially a downside of m&a if you want to talk about it in the larger contest. >> a lot of what you will see, companies saying i can automate, do things, cane have three people do things instead of four. frankly look i think business is good in this country, quoting union pacific jack koraleski who is hiring

let's not forget the mag any of sit gain you got for priceline or the absurd 239% premium that merck paid for i dentics. it's time to cover your shorts, before something you're betting against gets acquired, too. how about the rebounds in tesla? i still think that's overdone, but tesla, solar city, amazon, netflix, the cold stocks bouncing back to levels not even possible a few weeks ago. the fear that the ideologues who don't trust the feds stirred up literally for years is that when the fed tapered the bond-buying program, it would destroy the market. no one who fomented this fear has ever been held accountable. i get held accountable including things i didn't do or statements i didn't make. but this is what really g lly g me. as investor struggle to digest fresh fear, they're getting a steady diet of good news. -- aren't we entitled to savor the tasty takeovers? did anyone in the press taste the joy of the bidding war that caused the 70% rally in hillshire brands? how about digesting the 19% gains that shareholders of williams got today, because the company took a controlling stak

is merck's.als for melanoma. really these are getting closer to the market, yes. >> you mentioned astrazeneca. at the end of the day there was a bid, a bid that wasn't from pfizer. astrazeneca said, look, we should stand alone. the argument against pfizer is because we have a pipeline, we don't want to be damaged. we think it's valuable. is the initial stuff out of asco suggest that maybe that was the right call? >> i think so. i think astrazeneca have shown enough at asco, certainly in their oncology pipeline that its reasons for saying and possibly pfizer undervalued its pipeline, possibly it's adding weight to this argument from the data. we have very positive results, a bit of a surprise in ovarian cancer. the company has already filed for registration for that therapy on its own. now we have a combination therapy where both drugs are astrazeneca's. it seems to be almost twice as effective and maybe caters for other patients as well. that's very positive. astrazeneca also involved with the me

new survey by merck activity family project, 1,000 moms with children age two to 12 reveal 42 percent of mothers said they try to recreate vacations of their childhood. >> i think that is right. >> 35 percent of moms said they somewhat try to do that and 13 percent said they he don't try to do it that much at all. i guess they have rotten memories of childhood vacations. 10 percent said they do not try to recreate their glory days. let's bring in jen. you like to go on vacation to florida sometimes. that is where you grew up. isis that your mote vacation. >> heck no, heck no, my vacations were vacation from his he double hockey sticks and you know what i'm talking about. there is four kids from my family and i'm the oldest, right. my mom grew up in rochester new york and i grew up in florida. she hated summer heat. she'd load up that station wagon and we would drive up north, sometimes it was atlanta, and i would be the oldest and i had to like feed my baby sister. i was 13 years older. i was feeding a toddler. we have a little brother. my mommies a huge national history buff. we'd go

merck paying nearly $4 million for a company that makes the hepatitis c medication and priceline.compay $2.6 billion to buy the online reservation business opentable.com. >>> president obama took action to help millions of college grads pay down student loan debt signing an executive order expanding a pr cap at 10% of a borrower's ry tards ping off th fordoans. >>> lots of auto industry news this week.ford had to lower the ga cit posted are r six of its vehic general motors issued its 38th recall of the year. 38th. for another type of defective talight systems.tsubhiou toyota recalled 2 million vehicles f a second ti ove ag ir ue. and a surprise move by tesla which is opening up its lo pent to any automaker that wants to make long-range electric cars saying the move will increase development of more and better electric vehicles, lead to more sales across the sector, and actually strengthen tesla's share of the market. >>> get all your business news on cnbc. >>> we want to remind you about nbc 10's grant challenge for a local nonprofit called 21st century solutions. there's a $50,000

merck is going to buy pharmaceuticals in a $3.8 billion deal did shares of the drugmaker surgeon 230% news. family dollar had a good day up following the adoption of a poison pill strategy after carl icahn disclosed a large stake in the company. and forecasting the economy will grow 3.5% in the second quarter. by the way, be sure to listen to the financial report three times per day coast-to-coast on the salem radio network. the pakistani taliban threatening more violence after claiming responsibly for last night's massive attack at the airport which left more than two dozen people dead. for more on the growing threat from the taliban and in nuclear talks, joined by fox news national security analyst kt mcfarland. thank you for being here and i'll is always so much to talk about. let's talk about what is going on in pakistan, always a tinderbox for terrorist events, what does this mean westmar. will we see more of this? >> he whole region is about to blow. the taliban, not just one taliban, there are a lot all fighting each other. they are basically like mafia tribes. they fight the g

then merck's acquisition, priceline's purchase of open table, causing short -- the stocks like red hat, workday, bio techs, not isis is terror group. big tech will probably move up tomorrow because of adobe adobe's terrific numbers. they've rebounded nicely from their lows. so let me say that as someone who comes out here every night and talks about stocks, i feel chastened by the declines these high fliers endured. i said it would take buyouts to drive these stocks higher and we got all three and that's why we've within going up. but what matters now that we've gone back is risk management. the other day, i talked about how tesla could be facing increased competition, maybe from bmw. whatever for that. that's okay. from now on, tesla's got to go up without me and it probably will go higher. i just cant make a case for its valuation. got plenty of cheap stocks that i like very much that i believe would do just fine. i'm okay watching tesla go higher here without me. i feel the same about amazon. exciting company. can't wait for david faber's special at the end of the month, however, i

tyson winning the food fight over hillshire brands, and merck making a big buy. >>> triple crown bluesrome energized horse racing, but his dramatic defeat in the belmont stakes has many wondering if we'll ever see another triple crown winner without a change in the rules. california chrome's jockey, victor espinosa, in the house here. we'll talk to him about that as well as racing's world money game in a business network exclusive. >>> and -- ♪ ♪

caterpillar is the biggest -- merck had been a big gainer. it's a milestone, a psychological number, and it represents the steady climb that we have seen both in the dow and the s&p 500. we're heading for six straight sessions of gains. there is the dow jones industrial average over one year. last time we saw the big number, that was 16,000, was november 2013. so talk about seven months. interestingly enough, simon, seven months before that is when we saw the 15,000 left. the point is you're rising 1,000 points every seven months, therefore you could rise another thousand point by january, sue, which would be a gain of almost 6% for january, if you kept up the pace, though that's a huge question. back to you. >> it sure is, but you never know in this market especially. thank you sarah and simon. >>> after a rough couple months, the russell 2000 has been staging a comeback. the russell small-cap index is up 2% this week, up 6% over the past month. seema mody is looking at what's driving the rebound for us. >> hi, sue. that's right. after tradi

merck, disney, cisco, microsoft. >> no, it's been the same story. we talk about how many times we talked ab the chips and the energy and pharmaceutical names. i never believed that, i think it you look at the pipelines and dividend yields, there are reasons i still like some of these names. it puts a bid under a lot of the sector and a lot of pressure on washington dc. these energy names and when sarah touched on something that is very important. in the options markets they have increased every day through yesterday when we had 20 million contracts trading. we have the volumes, they're coming back. what's the leg that pushes up to 1950. look at theway -- you look at those three, you can look at pe's that are very, very tolerable for anyone to buy. >> maryann, you're looking for what's cheap, is anything left? >> definitely, energy, semiconductors just came out of this multiyear base and they're not even close to their all-time highs. we also like the industrials. we are now wage competitive when you take in our energy costs, inflation, and a stable

huge deal today in the pharmaceutical industry, merck paid 238% premium as a pharmaceutical company forepatitis c, but this company has not even done very well. they believe we will continue our self-destructive ways. we know calorie counts, products to help us lose weight, stop smoking, live healthier lives and the biggest money in medicine today isn't stuff we we do to ourselves because we will drink, we will smoke and eat ourselves to death and big medicine know those it and wille big money off it. you are a fitness fanatic. you run 20,000 miles per day, but you must acknowledge we are self-destructive and a lot of money to be made on it. >> we talked about return on investment. another more we don't change our behavior, the more money they will make. this company is trying to bank even though we need drugs that have other options, the option right now is very expensive. they still bank on a fact we will have that. charles: the first thought is damn, i don't own it. or do you? 238% for a company that wasn't doing too good. >> is see what the trend is, these bigger pharmaceutical comp

we do have some health care names like johnson & johnson and merck, also dupont and exxon mobil helping to lead the way higher. it is still very much a stock picker's market. there are some individual standouts, even though the markets are just about maybe 30 points on the up side for the dow. >> thank you very much, dom. >>> the surge of unaccompanied minors migrating to the u.s. prompting how speaker john boehner today to urge president obama to send in the national guard to help deal with what he is calling national security and humanitarian crises. this is all as vice president biden heads to guatemala to discuss the causes of the rising tide. afl-cio's president saying we need reform now. media mogul rupert murdoch, reform can't wait. joining us from washington, d.c. and all way from par irss kale bayie hutchison. she'll be joining us in just a second. tamar, great to see you there. i think everyone agrees we do need reform, but we have a crisis on our hands. how do we deal with it now? >> yeah, we've been trying to get reform for ten years and all of a sudden comes this crisis at

merck's not going to get credit if it comes to market to treat hep c.n as an r&d spend? >> i have regarded it as the greatest ophthalmological franchise other than what reagar regeneron has with macular degeneration. they've figured out uses of botox, does that not take r&d or do they stick people all over the place and it turns out something works? no, it's r&d. >> valeant has to figure out a way to turn around the stock price. rick santelli in chicago. rick? >> good morning, david. well we are looking at treasury yields fairly close unchanged. depending what part of the curve you're looking at. go to the longer end, down a basis point, open the chart up to may 1st. you can clearly see, the fed meeting that's coming up, or the one in the rear view mirror 2.60 level very significant. let's look at the relationships between securities and overseas. look at what's going on on the yield curve, 5 versus 10s, today's new plflat under 90 fla. tens to bunds, 125 basis points. this is a 15-year, yes, 1-5, on the differential between the two rates. take one of t

merck is up 18%. then there's intel, johnson & johnson and microsoft.the upside by 25% just this year alone. that far outstrips the 4% or 5% gains in the broader market. what's interesting is the biggest point impacts. the dow is one of those price weighted indices so if you look at the biggest point impacts, always going to be names like caterpillar. names like johnson & johnson, merck, cbx, disney. those are the ones doing the best right now. if you look at the sectors in the s&p 500 that are leading the way higher it really is, like you said, all about those utility stocks and energy stocks. remember utilities and energy have been jockeying at least for a bit now over the last couple of months about what's been doing better. when you see utilities, one of the more defensive seconders leading the way higher you question whether or not the bulls are in charge right now because utilities you only buy them if you think things are going to go wrong. you want to collect a nice dividend check and don't want to expose yourself to the ups and downs of the ove

the merck will be headquartered in a building on north 2nd street. it currently operates out of a building miles away in suburban san jose. the "mercury news" plans to move in september. >>> new at 6:00 some people say kind of creepy and weird looking. don ford shows us the piece of macrame art inside a bart station that's coming down. >> reporter: millions of commuters have passed by this. this massive macrame example of public art has been hanging on the embarcadero station walls for 40 years. it was once orange. it was once clean. that was then. this is now. bart says now it's coming down. >> bart is taking it down. it seemed like a good idea at the time. anybody who looked at the fashions of the 1970s can tell you that not everything stands the test of time. >> reporter: the piece is called legs. it's over 50 feet tall. originally, it weighed 3.5 tons but now with four decades of bart and muni grime, no one knows how much it really weighs. it is fantastically dirty and the cost of removing such a huge piece is fantastic, too, more than a quarter

melissa: merck kel son is not squeaky-clean guy.e has been linked to gambling debts and -- >> whatever comes of this -- >> gambling is legal. >> this is terrible idea for a pro athlete to hang out with professional gambler? >> why. people do it all the time. >> why? >> jim -- >> the point is -- >> not a mafia figure. >> i don't think this is putting your stamp on activism to have a case fall apart. >> it is pretty obvious. >> i think -- >> pretty obvious. >> impending news -- >> no way. >> they didn't like the just to one place. they leaked it to multiple -- melissa: let me l back in for a second. we've been saying this is the year of activist investor whether dan loeb and ackman making a lot of noise and next year would be the year of backlash against the activist investor. do you think is the beginning of this and do they keep going after folks like carl? >> number quite honestly the computer or something saw a bun of questionable trades. >> three years ago. >> they started to look into it was nothing. sometimes a cigar is just a

. >> reporter: mcdaniel got more votes in the pry merck bimary, the 50% needed to win, sparking the runoffgroups already invested in mcdaniel as their best hope of defeating a senate gop incumbent redoubled efforts. >> the resurgence for this country starts right here the in mississippi. >> reporter: nervous traditional republicans from around the country, trying to beat back the tea party, are here too. the chamber of commerce, airing a hail mary tv ad, with former star quarterback and mississippi native brett favre. >> thad cochran always delivers, just like he did during katrina. >> reporter: a super pac supporting cochran is spending money courting democrats allowed to vote in the gop runoff. you're not a republican, are you? >> no, i'm not. >> reporter: especially african-americans, who want to help a republican helping them for years. jackie brand passed out 5,000 cochran flyers. >> traditionally, african-americans vote a certain party. and we -- >> reporter: democrat? >> democrat, right. and we wanted to raise the awareness to african-americans that we do have a stake in this runoff